Traub Capital Management LLC Makes New $190,000 Investment in Johnson & Johnson $JNJ

Traub Capital Management LLC bought a new position in Johnson & Johnson (NYSE:JNJ) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 1,243 shares of the company’s stock, valued at approximately $190,000.

Other hedge funds also recently made changes to their positions in the company. GFG Capital LLC bought a new stake in Johnson & Johnson in the 2nd quarter worth approximately $35,000. Stone House Investment Management LLC bought a new stake in Johnson & Johnson in the first quarter worth $47,000. 1248 Management LLC purchased a new stake in Johnson & Johnson during the first quarter valued at $48,000. Harvest Fund Management Co. Ltd bought a new position in Johnson & Johnson during the first quarter valued at $52,000. Finally, Pandora Wealth Inc. purchased a new position in shares of Johnson & Johnson in the 1st quarter worth $65,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Shares of JNJ opened at $203.04 on Thursday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The company has a 50 day moving average price of $187.24 and a 200-day moving average price of $170.99. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $203.48. The stock has a market capitalization of $489.18 billion, a PE ratio of 19.60, a PEG ratio of 2.19 and a beta of 0.38.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.6%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.16% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. JPMorgan Chase & Co. upped their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Tuesday, September 16th. Morgan Stanley set a $190.00 price objective on Johnson & Johnson in a research report on Wednesday, October 15th. Scotiabank assumed coverage on Johnson & Johnson in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $230.00 target price for the company. Erste Group Bank upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Wednesday, July 23rd. Finally, Daiwa Capital Markets raised shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective for the company in a research note on Monday, October 20th. Four equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $201.05.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.